Product Details
Ilaris
Canakinumab150 mg/mL
Solution for Subcutaneous Injection
Single-Use 2-mL Glass Vial (Preservative-Free)
DIN/PIN/NPN
02460351
Manufacturer
Novartis Pharma Canada Inc.
Formulary Listing Date
2018-04-19
Unit Price
106.6667
Amount MOH Pays
106.6667
Coverage Status
Exceptional Access Program Product
ODB Formulary Therapeutic Classification
Therapeutic Note
NO
ATC Code
L04AC08
Interchangeable Products
NOLU Clinical Criteria
NOEAP Criteria
Therapeutic Class | Reimbursement Criteria |
---|---|
Metabolic/Genetic Modifiers | Canakinumab
Muckle-Wells Syndrome: The patient has a diagnosis of Muckle-Wells Syndrome (MWS) based on meeting each of the following confirmatory results:
If a patient is without NLRP3 mutation, a request will be considered on a case-by-case basis if the other confirmatory criteria are met and if the exclusion criteria are not met. However, the initial approval would be for 6 months; if the patient demonstrated a sustained SAA level below 10 mg/L, a renewal of funding for a 1-year approval period would be considered. Initial Approval Period: 1 year NOMID Syndrome: The patient has a Diagnosis of Neonatal-Onset Multisystem Inflammatory Disease (NOMID) based on meeting each of the following confirmatory results:
If a patient is without NLRP3 mutation, a request will be considered on a case-by-case basis if the other confirmatory criteria are met and if the exclusion criteria are not met. However, the initial approval would be for 6 months; if the patient demonstrated a sustained SAA level below 10 mg/L, a renewal of funding for a 1-year approval period would be considered. Initial Approval Period: 6 months For Both Indications For all patients, the treatment is supervised by medical specialists with knowledge in the management of CAPS (Cryopyrin-Associated Periodic Syndromes). The approved dosage will be:
For all patients, funding requests will be denied if any of the exclusion criteria is met:
Renewal Criteria: Confirmation from the Patient’s physician that the patient has benefited or continues to benefit from therapy with Ilaris, is expected to continue to do so and that each of the following is met:
The approved dosage for Subsequent Approvals is the same as Initial Approvals. EAP Drug Request Form: |